RxDoctor Payments Data

Corine Bowman, MD

Family Medicine · Bossier City, LANPI 1841241007

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 64 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$626
  • Amgen$150
  • Merck$125
  • Astellas Pharma US Inc$123
  • Viiv Healthcare Company$105
  • Pfizer$73
  • plus $364 from 11 others

What the payments were for

  • Food & beverage$1,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,565 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$10,744
Medicare patients
28
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala64$258,536
JardianceEmpagliflozin116$117,977
OzempicSemaglutide47$60,901
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$47,503
MounjaroTirzepatide25$44,129
TrulicityDulaglutide24$40,275
LinzessLinaclotide57$37,723
TivicayDolutegravir Sodium16$37,385
JanuviaSitagliptin Phosphate23$30,230
DescovyEmtricitabine/Tenofov Alafenam12$26,428
EliquisApixaban26$26,083
Tresiba Flextouch U-200Insulin Degludec23$24,691
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,602
Breo ElliptaFluticasone/Vilanterol21$10,879
MyrbetriqMirabegron16$9,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$30$332,46788 claims
Boehringer IngelheimJardiance$30$117,977116 claims
Lilly USA, LLCMounjaro, Trulicity$21$84,40449 claims
AbbVieLinzess$21$37,72357 claims
Viiv Healthcare CompanyTivicay$105$37,38516 claims
PfizerEliquis, Premarin, Prempro$73$35,18052 claims
MerckJanuvia$125$30,23023 claims
AstraZenecaBreztri Aerosphere, Symbicort$67$15,81030 claims
Astellas Pharma US IncMyrbetriq$123$9,21516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →